"Semaglutide is best known as a weight-loss drug. But the Nice recommendation is specifically about preventing heart attacks and strokes. The weekly injections will be an extra treatment, offered on top of medicines people are already taking, such as statins."
"Clinical trials found semaglutide reduces the risk of a heart attack, stroke or cardiovascular death. Crucially, this benefit was seen before significant weight loss occurred, suggesting the drug works directly on the heart and blood vessels, not just through weight loss."
"Previous analysis found semaglutide reduced the risk of major cardiac events by 20%. The findings suggested the drugs could have wider benefits for patients beyond weight loss, so should not be restricted to the most obese patients."
NHS England plans to offer semaglutide injections to over 1 million individuals at risk of cardiovascular events. The National Institute for Health and Care Excellence recommends these injections for people with a BMI of 27 or above who have experienced serious heart issues. Semaglutide, known for weight loss, also directly reduces heart attack and stroke risks. Clinical trials indicate its effectiveness in preventing major cardiac events, independent of weight loss. The treatment will complement existing medications and lifestyle changes for high-risk patients.
Read at www.theguardian.com
Unable to calculate read time
Collection
[
|
...
]